ASACOL TABLET (ENTERIC-COATED)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

MESALAZINE

可用日期:

ALLERGAN INC

ATC代码:

A07EC02

INN（国际名称）:

MESALAZINE

剂量:

400MG

药物剂型:

TABLET (ENTERIC-COATED)

组成:

MESALAZINE 400MG

给药途径:

ORAL

每包单位数:

180

处方类型:

Prescription

治疗领域:

ANTI-INFLAMMATORY AGENTS

產品總結:

Active ingredient group (AIG) number: 0116808001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2020-07-17

产品特点

_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ASACOL
TM
5-aminosalicylic Acid Enteric Coated Tablets
Tablets, 400 mg, Oral
Mfr. Std.
Lower Gastrointestinal Anti-inflammatory
Allergan Inc.
85 Enterprise Blvd., Suite 500
Markham, Ontario
L6G 0B5
www.allergan.ca
Date of Preparation:
June 11, 1985
Date of Revision:
March 18, 2021
Submission Control No: 245536
_ _
_ _
_Page 2 of 25_
RECENT MAJOR LABEL CHANGES
WARNINGS AND PRECAUTIONS, Renal
04/2020
WARNINGS AND PRECAUTIONS, Acute Intolerance Syndrome
03/2021
WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding
03/2021
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Recommended Dose and Dosage Adjustment
....................................................... 5
4.2
Administration
........................................................................................................
5
4.3
Missed Dose
..........................................................................................................
6
5
OVE